Related MeSH Hierarchy (9)
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Adenocarcinoma » Carcinoma, Renal Cell
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Urogenital Neoplasms » Urologic Neoplasms » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Urologic Neoplasms » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urologic Diseases » Kidney Diseases » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urogenital Neoplasms » Urologic Neoplasms » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urologic Diseases » Kidney Diseases » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Urologic Neoplasms » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Kidney Diseases » Kidney Neoplasms » Carcinoma, Renal Cell
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Urologic Neoplasms » Kidney Neoplasms » Carcinoma, Renal Cell
Description
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. MeSH
Hierarchy View
Phase 3 Indicated Drugs (38)
Phase 2 Indicated Drugs (186)
allogeneic hematopoietic stem cells (Hemacord)
anti-ny eso-1 t-cell receptor pbl
autologous alpha-dc1/tbva vaccine
Phase 1 Indicated Drugs (165)
dec-205/ny-eso-1 fusion protein cdx-1401
gvax pancreatic cancer vaccine
hyperacute-renal cancer vaccine
Other Experimental Indicated Drugs (25)
Organization Involved with Phase 4 Indications (21)
Organization Involved with Phase 3 Indications (72)
Cancer and Leukemia Group B (CALGB)
Central European Cooperative Oncology Group
European Organisation for Research and Treatment of Cancer
French Immunotherapy Intergroup
Gruppo Oncologico Italiano di Ricerca Clinica
HonorHealth Research Institute
Huazhong University of Science and Technology
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
National Institutes of Health (NIH)
Oregon Health and Science University
Royal Marsden Hospital NHS Trust
Shanghai Junshi Bioscience Co.,Ltd.
Organization Involved with Phase 2 Indications (301)
Academic and Community Cancer Research United
Associació per a la Recerca Oncologica, Spain
Associacio Per la Recerca Oncológica
Association of Urogenital Oncology (AUO)
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
Auckland District Health Board
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Azienda Ospedaliera San Gerardo di Monza
Badalona Hospital Germans Trias i Pujol
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Big Ten Cancer Research Consortium
Blokhin's Russian Cancer Research Center
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Central European Society for Anticancer Drug Research (CESAR)
Centro di Riferimento Oncologico - Aviano
Chinese Academy of Medical Sciences
City of Hope National Medical Center
Clinical Research Technology S.r.l.
Clinica Universidad de Navarra
Fundacion Instituto Valenciano de Oncologia
Gottfried Wilhelm Leibniz Universität Hannover
Gruppo Italiano Carcinoma Renale
GZA Ziekenhuizen Campus Sint-Augustinus
Hoag Memorial Hospital Presbyterian
Hoosier Cancer Research Network
Hospital Universitario Central de Asturias
Infinity Pharmaceuticals, Inc.
Instituto do Cancer do Estado de São Paulo
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Istituto Clinico Humanitas - Rozzano (MI), Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori
Italian Trial in Medical Oncology
King Faisal Specialist Hospital
Korean Urological Oncology Society
Ligue contre le cancer, France
Ludwig Institute for Cancer Research
Medical University of South Carolina
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
National Heart, Lung, and Blood Institute (NHLBI)
New Mexico Cancer Care Alliance
Ospedale Fatebenefratelli di Roma
Our Lady of Mercy Cancer Center
Our Lady of Mercy Medical Center
People's Liberation Army of China
Russian Academy of Medical Sciences
Saint Francis Memorial Hospital
Scottish Clinical Trials Research Unit
Shenzhen Hank Bioengineering Institute
Sinobioway Cell Therapy Co., Ltd.
Southern China Urology Cancer Consortium
Spanish Oncology Genito-Urinary Group
Sunshine Lake Pharma Co., Ltd.
Swiss Group for Clinical Cancer Research
Taipei Veteran General hospital
The Christie NHS Foundation Trust
The University of Texas, Dallas
Universidad Autonoma de Barcelona
Universidad Complutense de Madrid
University of California, Berkeley
University of California, Davis
University of California, San Diego
University of Colorado, Denver
University of Medicine and Dentistry of New Jersey
University of Southern California
University of Texas, San Antonio
Urological Institute of Northeastern New York
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (60)
Organization Involved with Other Experimental Indications (6)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
